The Board of Directors of MolMed S.p.A. (MLM.MI), chaired by Professor Claudio Bordignon, today reviewed and approved the draft financial statements at 31 December 2012. The most relevant elements concerning product development and activity progress were....
More
The Board of Directors of MolMed S.p.A. (MLM.MI), chaired by Professor Claudio Bordignon, today reviewed and approved the draft financial statements at 31 December 2012. The most relevant elements concerning product development and activity progress were.
- TK: started registrative procedures and dossier preparation to file a market authorization application through an accelerated procedure (Conditional Marketing Authorisation) with the European Medicines Agency, based on efficacy and safety data obtained in more than 120 patients treated so far;
- NGR-hTNF: completed enrolment in the registrative Phase III trial in relapsed malignant pleural mesothelioma (NGR015); moreover significant efficacy results have been obtained from the randomised Phase II studies in non-small cell lung cancer with squamous histology and in soft tissue sarcomas;
- Production for third parties: increased revenues from the development of new cell and gene therapy treatments to € 4.6 million, up 71% com
Less
